Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics' weight-loss drug VK2735 shows strong efficacy, likely leading to an acquisition by a large pharmaceutical firm, in my opinion. But the firm faces significant risks and competition. The timeline for a takeover bid may be longer than expected, and the acquisition price could be lower than bullish estimates. Marketing VK2735 independently or finding a strategic partner will be challenging, yet the stock is a buy for patient, risk-tolerant, long-term investors.

Viking Therapeutics Is A Buy For Some Investors, But Beware The Sizeable Risks

Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, pitching it to one day compete in a >$150bn market. Viking's strong financial position, upcoming Phase 3 trials, and potential oral formulation of VK-2735 justify upgrading the stock to a “Buy.”.

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Amgen

Many healthcare companies are working hard now on developing the next big weight loss drug. Industry veteran Amgen has an exciting treatment that may not require frequent injections.

Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?

Viking Therapeutics Inc. NASDAQ: VKTX, a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%.

Viking Therapeutics Is Having a Year to Remember: Time to Buy?

Moderna

Vertex Pharmaceuticals

Moderna hopes to win approvals for 10 programs by 2027. Vertex Pharmaceuticals could have multiple new blockbuster drugs on the market over the next few years.

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

Citigroup

Coca-Cola

Jim Cramer is probably the closest thing we have to stock market superstar influencer.

Not So Fast Jim Cramer, You Should Buy These 3 Stocks He Says to Sell

Sarepta Therapeutics

Viking Therapeutics is inching closer to launching a weight loss product with multibillion-dollar potential. Sarepta Therapeutics continues to develop medicines for rare diseases whose sufferers have few options.

These 2 Biotech Stocks Are Set to Soar

Roche, a big pharmaceutical company, recently shared details from an early-stage trial with its oral anti-obesity candidate. Roche's oral anti-obesity candidate outperformed a similar candidate from Viking Therapeutics in terms of efficacy.

Viking Therapeutics: A Bad Result for Roche's Weight-Management Pill Is Great News for Oral VK2735

Many investors and prognosticators think one investigational drug in particular has vast potential. If ultimately approved, VK2735 would surely be competitive in a highly popular segment.

Why Investors Plowed Into Viking Therapeutics Stock Today

Altimmune

Structure Therapeutics Inc

Eli Lilly

Novo Nordisk

Karl-Hendrik Tittel / Getty Images There's also Altimmune (NASDAQ:ALT), whose pemvidutide treatment led to weight loss while preserving lean mass.

Five Top Obesity Stocks to Buy and Hold Long Term

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

CRISPR Therapeutics

These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have declined -- but they each offer solid long-term share performance potential.

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

An analyst initiated coverage of the biotech. He's optimistic about its future, to put it mildly.

Why Viking Therapeutics Stock Rocked the Market Today

Viking Therapeutics (VKTX) shares rose more than 10% Wednesday after J.P. Morgan analysts initiated coverage of the company with an "overweight" rating and a price target of $80 per share, calling the company's oral weight-loss drug currently in clinical trials "underappreciated.

Why Analysts Predict a November Surge for Viking Therapeutics Stock

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc VKTX with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65.

Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan

Insmed

TG Therapeutics

Aspen Aerogels

AST SpaceMobile

Cava Group, Inc.

Cinemark Holdings

On Holding AG

Sweetgreen

SL Green Realty

Western Alliance Bancorporation

XPO Logistics

Subscribers to  Chart of the Week  received this commentary on Sunday, September 8.

These 12 Stocks are Ripe for a Short Squeeze

ARM Holdings PLC

MicroStrategy Incorporated

The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.

Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $54.78, signifying a +1.2% move from its prior day's close.

Viking Therapeutics, Inc. (VKTX) Laps the Stock Market: Here's Why

Corbus Pharmaceuticals Holdings

Avidity Biosciences

The release of OpenAI‘s ChatGPT chatbot in November 2022 unleashed a frenzy of investor interest in artificial intelligence that propelled Nvidia (NASDAQ:NVDA) to the forefront of the industry.

3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024

Viking Therapeutics is developing a weight management treatment candidate that is similar to Eli Lilly's Zepbound. Analysts' estimates for Viking Therapeutics point to huge gains for the stock over the next 12 months.

Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?

This stock already beat Nvidia's performance in the first half. This player operates in a market that could reach $100 billion by the end of the decade.

Prediction: This Biotech Stock Will Outperform Nvidia in the Second Half of the Year

Viking Therapeutics, Inc. (VKTX) reachead $58.10 at the closing of the latest trading day, reflecting a -0.5% change compared to its last close.

Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.

Viking Surges 342% in the Past Year: How Should You Play the Stock?

Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite competition from Eli Lilly and Novo Nordisk, VK2735's unique oral formulation could position Viking as a strong contender in the obesity drug market. VKTX's financial stability, with $942 million in cash and equivalents, supports its ongoing and future clinical trials, making it a viable long-term investment.

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Roche Holding AG

The weight-loss drugs market could be worth up to $144 billion within six years. And a bevy of pharma stocks could get a lift.

News for Viking Therapeutics Stock (VKTX)